RiskReveal is a 14-gene molecular treatment stratification test to identify patients with Stage IA, IB and IIA non-squamous NSCLC who may be at low- or high-risk of having a recurrence and likely benefit from adjuvant chemotherapy.

RiskReveal is appropriate for all patients with Stage IA, IB or IIA non-squamous non-small cell lung cancer (NSCLC) who have undergone surgical resection and are now being considered for adjuvant treatment in the next stage of their care.

Results classify patients into low, intermediate, or high-risk of disease recurrence. In a non-randomized, prospective study of 250 patients who were surgically resected at a single institution, patients in the high- and intermediate-risk categories who were treated with adjuvant chemotherapy had significantly better survival than high- and intermediate-risk patients who did not receive chemotherapy.

RiskReveal has been clinically validated in two independent cohorts with close to 1400 patients (Kratz et al, Lancet, 2012).

A prospective study found that test-identified high/intermediate risk patients who were treated with adjuvant platinum-based chemotherapy had 91.7% 5-year disease-free survival (DFS) compared to 48.9% 5-year DFS for high/intermediate risk patients who did not receive chemotherapy. RiskReveal-identified low-risk patients had a disease-free survival (DFS) of 93.8% without adjuvant chemotherapy (Woodard GA, et al. Clinical Lung Cancer, 2018).

The significant difference in survival between treated vs. untreated high/intermediate-risk patients was reinforced in an expanded 250-patient prospective cohort, in which most patients were stage IA (Woodard GA, et al. Clin Lung Cancer, 2021).

See a complete list of publications for more information

Contact us at 1-844-662-6298 or cs@razorgenomics.com to set up an account.

You may then order the RiskReveal test, track testing progress and access test results in your physician portal.

Razor Genomics will provide a FFPE tissue shipping kit with detailed sample preparation and shipping instructions. We accept a tissue block or slides.

Results are typically ready within 10 business days from the time we receive the specimen.

We accept all forms of insurance including Medicare. Medicare covers the RiskReveal test, but we are currently out of network with other insurances. Once we have completed a patient’s test, we send them a letter explaining our insurance and financial assistance process. Patients who would like to be pre-qualified for financial assistance, or have any questions regarding insurance billing, can contact us at 1-844-662-6298.